Proliferating Patents, Lawsuits Stave Off Pharmas’ Generic Competitors

Why It Matters

The practice inflates drug costs, delays generic entry, and erodes the competitive balance the Hatch‑Waxman Act was designed to create, impacting patients and healthcare spenders.

Key Takeaways

• Serial litigation leverages multiple overlapping patents
• Each Hatch‑Waxman lawsuit adds ~30‑month FDA stay
• Continuation patents create patent thickets
• Generic firms face $6 M+ per lawsuit
• Potential reforms target patent‑thicket abuse

Pulse Analysis

The Hatch‑Waxman Act of 1984 was a landmark reform that streamlined generic entry by allowing abbreviated applications and patent certifications. Initially, a drug carried only a handful of patents, and successful challenges quickly lowered prices by roughly half. Over the past decade, however, manufacturers have begun filing dozens of continuation patents per product, turning a single drug into a dense patent thicket. This shift has fundamentally altered the act’s balance, giving brand‑name firms a legal lever to stall competition.

Serial litigation exploits that lever. When a generic company files an ANDA, the originator can sue on any listed patent, triggering a 30‑month stay while the case proceeds. Companies then file additional suits on other patents if the first is invalidated, creating a cascade of legal battles. Real‑world examples include AbbVie’s Humira, shielded by 105 patents for over 20 years, and Sandoz’s multi‑year fights over Bimatoprost and Myrbetriq, each round costing more than $6 million—often exceeding the drug’s development expense.

The broader impact is a prolonged monopoly that keeps drug prices high and delays savings for patients and payers. As major innovators approach patent cliffs that could shave billions from their revenue streams, the incentive to build patent thickets intensifies. Policymakers are therefore examining reforms—such as tightening continuation‑patent rules and limiting repetitive litigation—to restore the competitive intent of Hatch‑Waxman. Aligning patent protection with genuine innovation, rather than strategic market extension, will be crucial for sustainable drug pricing and access.